Abstract Number: 1494 • ACR Convergence 2023
The Effect of Belimumab on Steroid Use in Patients with SLE: Results from a Retrospective Observational Study of Real-World Data from a US Rheumatology Provider Network
Background/Purpose: While oral CS (OCS) are the mainstay of SLE therapy, prolonged use is associated with organ damage and early mortality.1,2 Minimizing OCS use is…Abstract Number: 2487 • ACR Convergence 2023
Phase 2 Safety and Efficacy of Subcutaneous (s.c.) Dose Ianalumab (VAY736; Anti-BAFFR mAb) Administered Monthly over 28 Weeks in Patients with Systemic Lupus Erythematosus (SLE) of Moderate-to-Severe Activity
Background/Purpose: Ianalumab is a novel defucosylated human IgG1 mAb targeting the receptor for B cell Activating Factor belonging to the TNF Family (BAFF-R) providing potent…Abstract Number: 0003 • ACR Convergence 2023
Expanded Extrafollicular B Cells Were Improved by RTX in IgG4-related Disease
Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated disease characterized by fibrotic masses with expansion of IgG4-producing plasma cell in multiple organs such as pancreas, lacrimal…Abstract Number: 0730 • ACR Convergence 2023
NF-κB Signaling Is Critically Important for Functional Responses of ACPA-producing B Cell Clones from Patients with Rheumatoid Arthritis
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) play a role in rheumatoid arthritis (RA) pathogenesis, and their presence is associated with disease severity. Consequently, detailed analysis of…Abstract Number: 1502 • ACR Convergence 2023
Introduction of Belimumab Within Five Years of the Onset of Systemic Lupus Erythematosus (SLE) Contributes to the Better Therapeutic Response; A Multi-center Retrospective Cohort Study
Background/Purpose: Belimumab (BEL), B cell-targeted biologic agent for systemic lupus erythematosus (SLE), is cumulating evidence such as reducing glucocorticoids and preventing the progressionof organ damage.…Abstract Number: 2511 • ACR Convergence 2023
Superior SARS-CoV-2 Antibody Response Achieved in Rituximab-treated Patients When Vaccinated Against COVID-19 Before Compared to After Rituximab Initiation – Guidance for Future Vaccination Strategies
Background/Purpose: Rituximab (RTX) treatment significantly decreases the antibody response to COVID-19 vaccines, raising concerns about its use. However, unlike during the pandemic, most patients initiating…Abstract Number: 0004 • ACR Convergence 2023
CD22 X CD79b Bispecific Ab Potently Inhibits B Cell Activation and Plasmablast Accumulation
Background/Purpose: B cells contribute to the development and progression of autoimmune diseases through multiple mechanisms. Consequently, modulating B cell activation, B cell effector function, and…Abstract Number: 0731 • ACR Convergence 2023
ZEB2 Acts as a Crucial Transcriptional Regulator Governing Age-Associated B Cell Formation and Pathogenicity in Systemic Lupus Erythematosus
Background/Purpose: Age-associated B cells (ABCs) accumulate and contribute to the pathogenesis of systemic autoimmune diseases like lupus. Despite recent insights into the ontogeny and function…Abstract Number: 1511 • ACR Convergence 2023
B-Cell Recovery in a Randomized Controlled Trial of B-Cell Depletion with Obinutuzumab for the Treatment of Proliferative Lupus Nephritis
Background/Purpose: Patients with LN who received obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, with standard-of-care (MMF) immunosuppression (Phase II NOBILITY; NCT02550652; PMID 34615636) showed…Abstract Number: 2598 • ACR Convergence 2023
6 Months-follow up Data of Systemic Sclerosis Patients Treated with CD 19 Targeting CAR-T Cells
Background/Purpose: CD19-targeting CAR-T-cells showed remarkable improvements in autoimmune diseases including refractory lupus erythematodes (1,2) and inflammatory myopathy (3). Moreover, first data of a patient with…Abstract Number: 0005 • ACR Convergence 2023
Obexelimab Inhibits B Cell Activation and May Interfere with B Cell Chemotaxis in IgG4-Related Disease
Background/Purpose: Obexelimab is a bifunctional, non-cytolytic, humanized monoclonal antibody that binds CD19 and ligates FcγRIIb with high affinity. Data from a phase 2 clinical trial…Abstract Number: 0732 • ACR Convergence 2023
Should Complete B-cell Depletion Be Maintained in Patients Treated Long-term with Rituximab for Rheumatoid Arthritis?
Background/Purpose: Complete peripheral B cell depletion has been considered as a relevant indicator of short-term response to rituximab (RTX) in rheumatoid arthritis (RA). The purpose…Abstract Number: 1533 • ACR Convergence 2023
Long-term Use of Rituximab in Systemic Sclerosis: A Real-life Italian Multicentre Study
Background/Purpose: Rituximab(RTX) has been used for the management of systemic sclerosis(SSc). Its efficacy has been recently confirmed in a phase III clinical trial with extension…Abstract Number: 0006 • ACR Convergence 2023
Preclinical Characterization of a Novel anti-CD40 Antagonist Antibody-glucocorticoid Conjugate with Superior Preclinical Efficacy and Favorable Safety Profile
Background/Purpose: Glucocorticoids (GCs) are the first-line anti-inflammatory treatment for many autoimmune diseases, but long-term systemic administration of GCs is associated with unwanted side effects, which…Abstract Number: 0783 • ACR Convergence 2023
Tolerability of CAR T Cell Therapy in Autoimmune Disease
Background/Purpose: We have previously shown that CD19 CAR T cell therapy can lead to improvement of severe forms of B cell mediated autoimmune disease including…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 12
- Next Page »